2024-03-28T13:23:37Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_39D6FCC8E3FC
2024-03-23T02:13:21Z
serval:BIB_39D6FCC8E3FC
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
10.1158/1078-0432.CCR-12-2219
000312020400024
22977195
Cathomas
R.
author
Rothermundt
C.
author
Klingbiel
D.
author
Bubendorf
L.
author
Jaggi
R.
author
Betticher
D.C.
author
Brauchli
P.
author
Cotting
D.
author
Droege
C.
author
Winterhalder
R.
author
Siciliano
D.
author
Berthold
D.R.
author
Pless
M.
author
Schiess
R.
author
von Moos
R.
author
Gillessen
S.
author
Swiss Group for Clinical Cancer Research SAKK
contributor
article
2012
Clinical Cancer Research
1078-0432
1078-0432
journal
18
21
6049-6057
eng
60_published
true
peer-reviewed
Publication types: Journal Article ; Research Support, Non-U.S. Gov't